Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation ...
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...
Advanced lung cancer inflammation index (ALI) as a prognostic marker for locally advanced and metastatic cancer: A prospective study. Phase II study of disitamab vedotin (RC48) in combination with ...
Multigene NGS on tumor tissue accurately identifies pathogenic variants in EOC, supporting a tumor-first genetic testing model. The study found 94.3% of tumors had detectable variants, with 99.1% ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results